Everything below concerns somatotroph cell. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or loose powder |
| Solubility | Freely soluble in water | Salt form dissolves readily in aqueous buffer |
| Storage (lyophilized) | 2 to 8 °C | Protect from light and moisture |
| Common purity method | Reversed-phase HPLC | Reported as peak-area percentage |
| Identity confirmation | Electrospray mass spectrometry | Measured mass compared with theoretical value |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
== History == Effective pharmaceutical female sex-hormonal medications, including androgens, estrogens, and progestogens, first became available in the 1920s and 1930s, and might have been prescribed for transitions as early as the late 30s or 40s. The earliest report of hormone therapy in transgender women was published by Danish endocrinologist Christian Hamburger in 1953. One of his patients was Christine Jorgensen, who he had treated starting in 1950. Additional reports of hormone therapy in transgender women were published by Hamburger, the German-American endocrinologist Harry Benjamin, and other researchers in the mid-to-late 1960s. However, Benjamin had several hundred transgender patients under his care by the late 1950s, and had treated transgender women with hormone therapy as early as the late 1940s or early 1950s. In any case, Hamburger is said to be the first to treat transgender women with hormone therapy. One of the first transgender health clinics was opened in the mid-1960s at the Johns Hopkins School of Medicine. By 1981, there were almost 40 such centers. A review of the hormonal regimens of 20 of the centers was published that year. The first International Symposium on Gender Identity, chaired by Christopher John Dewhurst, was held in London in 1969, and the first medical textbook on transness, titled Transsexualism and Sex Reassignment and edited by Richard Green and John Money, was published by Johns Hopkins University Press in 1969. This textbook included a chapter on hormone therapy written by Christian Hamburger and Harry Benjamin.
=== Rail === Bromley is served by two main rail stations. Bromley South provides National Rail services to London Victoria (non stop, semi fast via Denmark Hill and stopping services via Herne Hill), London Blackfriars via Catford, Orpington, Sevenoaks via Swanley, Ramsgate via Chatham, Dover Priory via Chatham & Canterbury East and to Ashford International via Maidstone East. Bromley North provides shuttle services to Grove Park, where onward connections can be made for services to London Charing Cross & London Cannon Street via Lewisham. Finally, Shortlands railway station serves primarily residential areas immediately southwest of the town centre. Being one stop west of Bromley South, Southeastern and Thameslink services connect the station to London Victoria and London Blackfriars.
=== Soundproofing === Researchers demonstrated a graphene-oxide-based aerogel that could reduce noise by up to 16 decibels. The aerogel weighed 2.1 kilograms per cubic metre (0.13 lb/cu ft). A conventional polyester urethane sound absorber might weigh 32 kilograms per cubic metre (2.0 lb/cu ft). One possible application is to reduce sound levels in airplane cabins.
Sources: en.wikipedia.org
Following the conclusion of the First World War, production of the Pernod Fils brand was resumed at the Banus distillery in Catalonia, Spain (where absinthe was still legal), but gradually declining sales saw the cessation of production in the 1960s. In Switzerland, the ban served only to drive the production of absinthe underground. Clandestine home distillers produced colourless absinthe (la Bleue), which was easier to conceal from the authorities. Many countries never banned absinthe, notably the United Kingdom, where it had never been as popular as in continental Europe.
Tomatoes, with their umami flavor, are extensively used in Mediterranean cuisine as a key ingredient in pizza and many pasta sauces. Tomatoes are used in Spanish gazpacho and Catalan pa amb tomàquet. The tomato is a crucial and ubiquitous part of Middle Eastern cuisine, served fresh in salads (e.g., Arab salad, Israeli salad, Shirazi salad and Turkish salad), grilled with kebabs and other dishes, made into sauces, and so on. Tomatoes were gradually incorporated into Indian curry dishes after Europeans introduced them. A Kashmiri curry, rogan josh, often contains tomato; it may originally have been colored red with chili pepper, and tomatoes may characterize the Punjabi version of the dish. The modern British curry tikka masala often has a tomato and cream sauce.
=== Development === The episode was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. This was Carcieri's 19th writing credit, Fradley's 13th writing credit, McBride's 28th writing credit, and Hill's 14th directing credit.
positive antinuclear antibody (ANA) test. Patients with UCTD usually have positive ANA. a decrease in the number of white blood cells anemia abnormal nerve sensations in the extremities inflammation of the lining of the heart and/or lungs a decrease in platelet count Pulmonary involvement, such as nonspecific interstitial pneumonia, can be a complication of the disease.
Sources: en.wikipedia.org
TAVR I - Special Army Volunteer Reserve or 'Ever Readies', echoing the earlier nickname for the TAER, bringing the Regular Army to war establishment and replacing casualties. These were to be given extra training and equipment and could now be called out by Queen's Order rather than Royal Proclamation in anticipation of war and TAVR II - forces called 'The Volunteers', for whom the old call-out arrangements continued. This category was split further split into TAVR IIA (Independent), e.g.: 51st Highland Volunteers and TAVR IIB (Sponsored), e.g.: Central Volunteer Headquarters, Royal Artillery. In addition were various miscellaneous units, such as OTCs and bands e.g. Northumbria Band of the Royal Regiment of Fusiliers. In the face of a considerable Parliamentary battle, and a public outcry led by the County Associations, the government agreed to retain an additional 28,000 men in 87 'lightly armed' infantry units and a few signals units in a category called TAVR III, designed for home defence, but, months later in January 1968, these were all earmarked to be disbanded, with 90 becoming eight-man "cadres". In November that year, the call-out arrangements for TAVR II units were brought in line with TAVR I.
== See also == Chromatophore (the pigment cell type found in poikilotherm animals) Eye color Mole (skin marking) Tanning activator List of distinct cell types in the adult human body List of human cell types derived from the germ layers
=== Diplomatic relations === After the UDI, Rhodesia maintained several overseas missions, including Pretoria, and until 1975, Lisbon in Portugal and Lourenço Marques (now Maputo) in Mozambique. Since 1961, Rhodesia had an "Accredited Diplomatic Representative" with South Africa, heading a "Rhodesian Diplomatic Mission" or de facto embassy. Before South Africa left the Commonwealth that year, the then Southern Rhodesia had exchanged High Commissioners with the then Union of South Africa, but following the change in status, the Republic now had a "South African Diplomatic Mission" in Salisbury. During 1965, the government of Rhodesia made moves to establish a mission in Lisbon separate from the British Embassy, with its own accredited representative, having previously been able to establish its own consulate in Lourenço Marques, capital of Portuguese Mozambique. This prompted protests from the British government, which was determined that the representative, Harry Reedman, should be a nominal member of the British Ambassador's staff. For their part, the Portuguese authorities sought a compromise whereby they would accept Reedman as an independent representative but deny him diplomatic status. The Rhodesian Information Office in Washington remained open following UDI, but its director, Ken Towsey, and his staff were deprived of their diplomatic status. Previously, there had been a "Minister for Rhodesian Affairs" operating under the aegis of the British Embassy in Washington, as well representatives in Tokyo and Bonn.
==== MeSH D12.776.835.725.934 – prokaryotic initiation factors ==== MeSH D12.776.835.725.934.374 – prokaryotic initiation factor-1 MeSH D12.776.835.725.934.562 – prokaryotic initiation factor-2 MeSH D12.776.835.725.934.750 – prokaryotic initiation factor-3
==== Synthetic cannabinoids ==== Synthetic cannabinoids, members of the aminoalkylindole class, made its first appearance in 2008. It was given the name 'JWH' because a chemist called John W. Huffman synthesized them in the 1960s. Most synthetic analogs of cannabinoids mimic the structure of 9-tetrahydrocannabinol (THC), which makes them an agonist to the CB1(Type I) and CB2 (Type II) cannabinoid receptors. CB1 in particular, is expressed in the central nervous system and largely responsible for the psychoactive effect.. A typical agonist consists of the following components: head, linker core and tail. Altering the structure from each component will affect the drug's affinity to the cannabinoid receptors. For instance, when a fluoride or nitrile group is attached to the carbon chains, the affinity for CB1 will increase. The aromatic rings from the aminoalkylindole class also play the role of enhancing the affinity by forming a hydrophobic cavity to stabilize the CB1 receptors. As legislation becomes tightened under the monitoring of Early Warning System (EWS), attempts are made to alter the structure which produce new analogues such as the Cyclopropylindoles (UR-144) and adamantylindoles (APINACA).
Sources: en.wikipedia.org
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.
Mass spectrometry serves as the primary identity check, since the measured mass must agree with the theoretical value for a 44-residue sequence. Chromatographic retention time and peptide mapping supply supporting evidence.
Certificates of analysis and independent testing tie a specific lot to specific measured results. Without that link, purity and identity claims rest on the supplier's own statement rather than on verifiable data.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.